JP2024505630A5 - - Google Patents
Info
- Publication number
- JP2024505630A5 JP2024505630A5 JP2023542980A JP2023542980A JP2024505630A5 JP 2024505630 A5 JP2024505630 A5 JP 2024505630A5 JP 2023542980 A JP2023542980 A JP 2023542980A JP 2023542980 A JP2023542980 A JP 2023542980A JP 2024505630 A5 JP2024505630 A5 JP 2024505630A5
- Authority
- JP
- Japan
- Prior art keywords
- semi
- compound
- pharmaceutical preparation
- amount
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100526.9A GB202100526D0 (en) | 2021-01-15 | 2021-01-15 | Pharmaceutical formulation |
| GB2100526.9 | 2021-01-15 | ||
| PCT/GB2022/050083 WO2022153062A1 (en) | 2021-01-15 | 2022-01-14 | Pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024505630A JP2024505630A (ja) | 2024-02-07 |
| JP2024505630A5 true JP2024505630A5 (https=) | 2024-12-04 |
Family
ID=74678956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542980A Pending JP2024505630A (ja) | 2021-01-15 | 2022-01-14 | 医薬製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240082244A1 (https=) |
| EP (1) | EP4277606A1 (https=) |
| JP (1) | JP2024505630A (https=) |
| KR (1) | KR20230133285A (https=) |
| CN (1) | CN116710077A (https=) |
| AU (1) | AU2022208241A1 (https=) |
| CA (1) | CA3202029A1 (https=) |
| GB (1) | GB202100526D0 (https=) |
| MX (1) | MX2023008406A (https=) |
| WO (1) | WO2022153062A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220023266A1 (en) | 2018-12-07 | 2022-01-27 | Neurocrine Biosciences, Inc. | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia |
| JP7623365B2 (ja) | 2019-09-27 | 2025-01-28 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよび使用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA845180B (en) * | 1983-07-07 | 1986-02-26 | American Home Prod | Pharmaceutical composition containing a liquid lubricant |
| US9783550B2 (en) * | 2013-05-14 | 2017-10-10 | The Board Of Regents Of The University Of Texas System | Highly potent inhibitors of porcupine |
| KR102525131B1 (ko) * | 2014-10-08 | 2023-04-24 | 레드엑스 파마 피엘씨 | Wnt 신호 경로의 억제제로서의 N-피리디닐 아세트아미드 유도체 |
| CN111971063A (zh) * | 2018-04-06 | 2020-11-20 | 4阵营疗法公司 | 通过靶向调节基因信号传导网络治疗疾病 |
-
2021
- 2021-01-15 GB GBGB2100526.9A patent/GB202100526D0/en not_active Ceased
-
2022
- 2022-01-14 CA CA3202029A patent/CA3202029A1/en active Pending
- 2022-01-14 WO PCT/GB2022/050083 patent/WO2022153062A1/en not_active Ceased
- 2022-01-14 JP JP2023542980A patent/JP2024505630A/ja active Pending
- 2022-01-14 EP EP22701416.4A patent/EP4277606A1/en active Pending
- 2022-01-14 CN CN202280010206.5A patent/CN116710077A/zh active Pending
- 2022-01-14 MX MX2023008406A patent/MX2023008406A/es unknown
- 2022-01-14 AU AU2022208241A patent/AU2022208241A1/en active Pending
- 2022-01-14 US US18/271,913 patent/US20240082244A1/en active Pending
- 2022-01-14 KR KR1020237023066A patent/KR20230133285A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1903866B1 (en) | Improved delivery of tetrahydrocannabinol | |
| JP5753157B2 (ja) | 親水性薬剤の自己マイクロエマルジョン化経口医薬組成物およびその調製方法 | |
| JP6697779B2 (ja) | カルシフェジオール軟カプセル剤 | |
| WO2016022936A1 (en) | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts | |
| EP2062571B1 (en) | Self-emulsifying pharmaceutical composition with enhanced bioavailability | |
| JP2002509877A (ja) | 抗癌組成物 | |
| CN101627969B (zh) | 一种姜黄素自乳化给药系统及其制备 | |
| JP7525674B2 (ja) | デュタステリドを含む固形製剤およびその製造方法 | |
| WO2005070393A2 (en) | Directly compressible pharmaceutical composition of the rapamycin ester cci-779 | |
| JP2024505630A5 (https=) | ||
| US20160081965A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| JP2004043511A (ja) | サイクロスポリン含有軟質カプセル製剤 | |
| CA2800279A1 (en) | Oral dosage forms of bendamustine | |
| CN113784722B (zh) | 用于有不良渗透性的蛋白质、肽和小分子的口服递送的制剂 | |
| US20210137917A1 (en) | Pharmaceutical composition of nintedanib esylate | |
| EP3854384A1 (en) | Pharmaceutical formulation comprising abiraterone acetate | |
| Kazi | Lipid-Based Nano-Delivery for Oral Administration of Poorly Water Soluble Drugs (PWSDs): Design | |
| US20180021286A1 (en) | Stabilized dialkyl fumarate compositions | |
| EP2435022B1 (en) | Self-microemulsifying mitotane composition | |
| US6352718B1 (en) | Vasopressin antagonist formulation and process | |
| TWI280129B (en) | Pharmaceutical composition for oral administration of a pyrazole-3-carboxamide derivative | |
| KR102329411B1 (ko) | R-치옥트산 또는 이의 약학적으로 허용되는 염, 오일 및 분산보조제를 포함하는 약학조성물 | |
| KR102566464B1 (ko) | 자가유화형 나노에멀전을 이용한 경구 투여 제제 | |
| KR101058860B1 (ko) | 수소화 코코-글리세라이드를 이용한 난용성 약물의 자가유화형 나노에멀젼 조성물 | |
| EP1216033A1 (en) | Vasopressin antagonist formulation and process |